Guselkumab vs Risankizumab for Crohn's Disease

(CHARGE Trial)

This trial aims to compare the effectiveness of two treatments, guselkumab and risankizumab, for individuals with Crohn's Disease, a condition causing severe inflammation in the digestive tract. Participants will receive one of these treatments to determine which better manages symptoms. The trial targets those who have had Crohn's Disease for at least 12 weeks and are experiencing moderate to severe symptoms that significantly impact daily life. As a Phase 3 trial, it represents the final step before FDA approval, providing participants an opportunity to access potentially effective treatments early.

The trial protocol does not specify if you need to stop your current medications, but it mentions that you must follow the requirements for other medications used to treat Crohn's Disease as outlined in the study. It's best to discuss this with the trial team or your doctor.

A previous study found guselkumab to be safe for people with Crohn's disease over one year of treatment. Its safety profile matched that of a placebo, with no unexpected side effects reported. Another study over five years confirmed that guselkumab was well-tolerated, with most participants continuing treatment without major issues.

Research indicates that risankizumab is also well-tolerated. One study found no new safety risks, and its safety remained consistent over time. Another study reported that only 6.9% of patients experienced unwanted effects, with only a few discontinuing treatment due to these effects.

Researchers are excited about these treatments for Crohn's Disease because they offer a novel approach compared to traditional options like corticosteroids and immunosuppressants. Guselkumab works by targeting a specific protein called interleukin-23 (IL-23), which plays a key role in inflammation, and is administered as an induction dose subcutaneously followed by a maintenance dose every four weeks. Risankizumab also targets IL-23 but is initially given intravenously, switching to a subcutaneous injection every eight weeks, potentially offering greater convenience and different dosing flexibility. Both treatments focus on reducing inflammation more precisely, which could lead to fewer side effects and better management of Crohn's Disease symptoms.

This trial will compare Guselkumab and Risankizumab for treating Crohn's Disease. Studies have shown that Guselkumab delivers strong results, with up to 97.7% of patients experiencing symptom relief when continuing treatment over five years. Another study found that 56.1% of patients felt better at week 12, outperforming those who took a placebo.